Providing Veterans Essential Medications Act

The Providing Veterans Essential Medications Act (HR1970) was introduced in the House on March 10, 2025, and subsequently referred to the House Committee on Veterans' Affairs, and then to the Subcommittee on Health on March 27, 2025. This bill seeks to amend title 38, United States Code, to direct the Secretary of Veterans Affairs to reimburse State homes for the cost of, or to furnish, certain costly medications provided to veterans receiving nursing home care. The bill is in its early stages, having only been referred to committee, indicating a long legislative path ahead. The bill does not specify a direct funding amount but rather establishes a mechanism for federal reimbursement or direct furnishing of medications by the VA. This means the financial burden for specific high-cost medications for veterans in state nursing homes would shift from state homes to the VA. This change would guarantee federal reimbursement for drug suppliers, thereby increasing payment certainty and potentially expanding the addressable market for pharmaceutical manufacturers and distributors within the VA system. Actual funding would depend on subsequent appropriations to the VA. Structural winners under this proposed legislation would be pharmaceutical manufacturers and distributors. Companies like Johnson & Johnson ($JNJ), Pfizer Inc. ($PFE), Merck & Co., Inc. ($MRK), Eli Lilly and Company ($LLY), Amgen Inc. ($AMGN), and Gilead Sciences, Inc. ($GILD) would benefit from increased payment certainty and an expanded market for their high-cost medications. Healthcare distributors such as McKesson Corporation ($MCK) and Cardinal Health, Inc. ($CAH) would also see increased demand and guaranteed payment for their distribution services. CVS Health Corporation ($CVS), with its pharmacy benefit management and retail pharmacy operations, could also see benefits through increased prescription volume or distribution opportunities. Recent market data shows varied performance among these companies. Over the past 30 days, Pfizer ($PFE) and Merck ($MRK) have seen positive changes of +4.58% and +4.12% respectively, while Eli Lilly ($LLY) and Amgen ($AMGN) experienced declines of -5.72% and -6.81%. Johnson & Johnson ($JNJ) had a modest gain of +0.56%, and Gilead Sciences ($GILD) declined by -3.45%. Among distributors, McKesson ($MCK) declined by -8.01%, while Cardinal Health ($CAH) saw a -1.57% change. CVS Health ($CVS) also declined by -6.88%. The legislative steps remaining include committee consideration, potential floor votes in the House and Senate, and ultimately, presidential assent.